Biosynex (XPAR:ALBIO) Total Operating Expense: €115.70 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALBIO Biosynex SA XPAR:ALBIO
43 GF Score
Price €0.90
GF Value €2.37
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Biosynex Total Operating Expense?

Biosynex XPAR:ALBIO -0.88% 43 Total Operating Expense is €115.70 Mil as of Dec. 2025. GuruFocus rates XPAR:ALBIO with a GF Score™ of 43/100 and a GF Value™ of €2.37 (Possible Value Trap). The stock has 7 warning signs investors should review.

Biosynex's Total Operating Expense for the six months ended in Dec. 2025 was €41.64 Mil. Biosynex's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €115.70 Mil.

Biosynex Total Operating Expense Related Terms

Biosynex Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Biosynex's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosynex Total Operating Expense Chart

Biosynex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.30 67.27 86.54 93.76 115.70

Biosynex Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.69 47.83 45.93 74.06 41.64
XPAR:ALBIO
43GF Score
Biosynex SA XPAR:ALBIO
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosynex Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €115.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €115.70 Mil mean?
Biosynex (XPAR:ALBIO) has a Total Operating Expense of €115.70 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Biosynex and its competitors.
Is Biosynex's Total Operating Expense too high?
Biosynex's current Total Operating Expense is €115.70 Mil. Overall, Biosynex has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biosynex's Total Operating Expense compare to ABT and SYK?
Biosynex's Total Operating Expense of €115.70 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Devices & Instruments company?
A good Total Operating Expense depends on the Medical Devices & Instruments industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Biosynex and its competitors. Biosynex's current Total Operating Expense is €115.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosynex stock overvalued right now?
Based on GuruFocus' analysis, Biosynex (XPAR:ALBIO) is currently considered Possible Value Trap. The stock's GF Value™ is €2.37, compared to a current price of €0.90 — trading 61.9% below its estimated fair value. The current Total Operating Expense is €115.70 Mil. Biosynex's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Biosynex (XPAR:ALBIO), the current Total Operating Expense is €115.70 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biosynex (XPAR:ALBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biosynex stock appears to be undervalued. The current stock price of €0.90 is trading 61.9% below its estimated GF Value™ of €2.37. GuruFocus considers Biosynex to be Possible Value Trap.

Key valuation signals for XPAR:ALBIO:

  • Total Operating Expense: €115.70 Mil
  • GF Value™: €2.37 vs. price of €0.90 (61.9% below fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the XPAR:ALBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biosynex Business Description

Other Exchanges 0DL:Germany
Address 22 Boulevard Sebastien Brant, Illkirch, FRA, 67400
Biosynex SA is engaged in the research, development, and manufacturing of fast diagnosis tests on membrane support for health professionals. It manufactures and markets medical devices for screening, diagnosis.
43GF Score

Get the complete analysis for XPAR:ALBIO

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.90
Price
€2.37
GF Value